September 1st, 2013
A World Conference in My Backyard
M. Louis Handoko, MD PhD
A hometown fellow plunges headfirst into the 2013 ESC Congress.
September 1st, 2013
Pretreatment with Prasugrel Not Indicated in NSTEMI
Larry Husten, PHD
Pretreatment prasugrel for NSTEMI was not effective in the ACCOAST trial.
September 1st, 2013
ESC.13 Headquarters
CardioExchange Editors, Staff
Find all of our ESC.13 coverage here.
September 1st, 2013
Positive Results for Edoxaban in VTE/PE
Larry Husten, PHD
Findings from the Hokusai-VTE trial of edoxaban
September 1st, 2013
A Disruptive TASTE of the Future?
Larry Husten, PHD
Negative findings from a registry-based randomized trial of pre-PCI thrombus aspiration for STEMI patients
September 1st, 2013
Disappointing Results with Dabigatran for Mechanical Valves
Larry Husten, PHD
For more of our ESC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Despite being more durable than bioprosthetic valves, mechanical heart valves are often not chosen because of the requirement for […]
August 29th, 2013
Inexpensive Accelerometer Could Help Monitor Progress After Heart Surgery
Larry Husten, PHD
An inexpensive off-the-shelf fitness monitor can help physicians monitor and perhaps customize their treatment of patients after heart surgery, according to a new study from the Mayo Clinic published in the Annals of Thoracic Surgery. Although the mobility of patients after surgery has long been recognized as a significant predictor of outcome, the authors of the study note […]
August 29th, 2013
Managing Hypertension – Not as Easy as It Once Seemed
Paul A. Bergl, MD
A Chief Resident surveys the rapidly changing landscape of hypertension management.
August 28th, 2013
New Drug Found Safe and Effective in Pulmonary Arterial Hypertension — But Does It Save Lives?
Larry Husten, PHD
Macitentan, a new drug for pulmonary arterial hypertension (PAH), appears to be safe and effective, but it is unclear whether it offers any significant advantages over currently available drugs. The drug, a dual endothelin-receptor antagonist, is under development from Actelion as an enhanced version of bosentan (Tracleer). The results of a phase 3 trial, SERAPHIN (Study with an Endothelin […]
August 28th, 2013
American Heart Association Announces Late-Breaking Clinical Trials
Larry Husten, PHD
There are still a few days left in August, and the European Society of Cardiology meeting doesn’t start until this weekend in Amsterdam. Nevertheless, the American Heart Association has released the list of late-breaking clinical trials for its annual meeting in November. Late-Breaking Clinical Trials 1: Acute Cardiovascular and Cerebrovascular Care Sunday, Nov 17, 2013, 4:00 PM – […]
